18 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Lymphatic Diseases"
Show Display Options
Rank Status Study
1 Recruiting S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate
2 Recruiting S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: vincristine sulfate
3 Recruiting Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Drug: lenalidomide
4 Recruiting Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial
Conditions: Leukemia;   Lymphoma
Intervention: Other: biologic sample preservation procedure
5 Recruiting Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Other: biologic sample preservation procedure
6 Recruiting Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
7 Recruiting Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Conditions: Lymphoma;   Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure;   Other: informational intervention
8 Recruiting Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Estrogen Receptor-negative Breast Cancer;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HER2-negative Breast Cancer;   Intraocular Lymphoma;   Male Breast Cancer;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Progesterone Receptor-negative Breast Cancer;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Breast Cancer;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Breast Cancer;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Breast Cancer;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IIIC Breast Cancer;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Breast Cancer;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   Triple-negative Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: veliparib;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
9 Recruiting Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Biological: anti-thymocyte globulin;   Biological: rituximab;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
10 Recruiting Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Condition: Lymphoma
Intervention: Biological: ofatumumab
11 Recruiting Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Conditions: Lymphoma;   Neurotoxicity;   Therapy-related Toxicity
Interventions: Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Drug: lenalidomide
12 Recruiting Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia
Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: laboratory biomarker analysis
13 Recruiting Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Condition: Leukemia
Interventions: Biological: filgrastim;   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: lenalidomide;   Drug: pentostatin
14 Recruiting Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection
Conditions: Breast Cancer;   Lymphedema;   Perioperative/Postoperative Complications
Interventions: Behavioral: exercise intervention;   Other: educational intervention;   Procedure: assessment of therapy complications;   Procedure: complementary or alternative medicine procedure;   Procedure: management of therapy complications;   Procedure: quality-of-life assessment;   Procedure: therapeutic conventional surgery
15 Recruiting Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: vorinostat;   Drug: bortezomib;   Other: laboratory biomarker analysis
16 Unknown  Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Xcellerated T Cells
17 Recruiting Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Conditions: Solid Tumors;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Glioblastoma Multiforme;   Oligodendroglioma;   Hepatocellular Carcinoma;   Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: CC-122 HCL
18 Recruiting Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib

Indicates status has not been verified in more than two years